文献速递药物不良反应与药物警戒

四种COVID-19疫苗免疫后报告不良事件频率的描述

Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
PubMed 文献 · Drug Saf · 2022-03-21

荷兰Lareb中心采用前瞻性队列事件监测,分析27554名接种一剂和20682名完成免疫的参与者患者报告结局。任何AEFI报告率从辉瑞约53%到Moderna约94%,严重AEFI频率低,最高为阿斯利康0.228%。首次接种阿斯利康和强生、第二剂Moderna报告AEFI最多,辉瑞最低;女性和年轻人报告更多。

要点

  • 任何AEFI报告率辉瑞约53%至Moderna约94%,严重AEFI频率低。
  • 严重AEFI最高为阿斯利康疫苗0.228%。
  • 女性和年轻人报告AEFI多于男性和老年人。

核心结论

  • 大规模队列显示任何AEFI报告率高但严重AEFI频率低,不同疫苗品牌、年龄、性别和既往感染史间存在差异。

研究设计与样本

  • 荷兰Lareb中心前瞻性队列事件监测(CEM),分析27554名接种一剂和20682名完成免疫参与者的患者报告结局。

主要发现

  • 任何AEFI报告率范围约53%(辉瑞)至约94%(Moderna)。
  • 严重AEFI频率最高为阿斯利康疫苗0.228%。
  • 首次接种阿斯利康和强生、第二剂Moderna报告AEFI最多,辉瑞最低。
  • 既往COVID-19感染者在首次接种后报告常见系统性AEFI多于第二次接种后。
  • 女性和年轻人分别比男性和老年人报告更多AEFI。

临床怎么用

  • 临床应告知接种者任何AEFI常见但严重事件罕见,尤其关注女性和年轻人及特定疫苗剂次后的反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The rapid rollout of coronavirus disease 2019 (COVID-19) vaccines for a large proportion of the population necessitates a strong emphasis on safety. Complementary to the existing spontaneous reporting system, The Netherlands Pharmacovigilance Centre Lareb conducted patient-reported cohort event monitoring (CEM). OBJECTIVE: The primary aim was to investigate differences in the frequencies of any and commonly reported, 'well-known', systemic adverse events following immunization (AEFIs) with four COVID-19 vaccines (Pfizer's Comirnaty®, Moderna's Spikevax®, AstraZeneca's Vaxzevria® and the Janssen vaccine). As a secondary aim, we analyzed the frequencies of well-known systemic adverse events after the first and, if applicable, second COVID-19 vaccinations, taking into account age, sex and prior COVID-19 infection. METHODS: Patient-reported outcomes (PROs) in the Netherlands starting in February 2021 were analyzed using a prospective cohort design. RESULTS: Data of 27,554 participants who received one vaccination and 20,682 participants who received complete immunization were analyzed. The percentage of patients reporting any AEFI was high and ranged from approximately 53% for the Pfizer vaccine to approximately 94% for the Moderna vaccine. The frequency of serious AEFIs was low, with the highest frequency found for the AstraZeneca vaccine (0.228%). AEFIs were most often experienced by participants receiving the first dose of the AstraZeneca and Janssen vaccines and the second dose of the Moderna vaccine; the Pfizer vaccine was associated with the lowest rate of AEFIs. Participants with a COVID-19 history before vaccination experienced commonly reported systemic AEFIs more frequently after the first vaccination than after the second vaccination. Women and young people experienced more AEFIs than men and older people, respectively. CONCLUSIONS: The analysis of a large cohort provides important information about the rates of AEFIs across age groups, among brands of vaccines and between those with and without prior COVID-19 infection. Participants reported a high number of AEFIs in general, but the frequency of serious AEFIs was low.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Kant A, Jansen J, van Balveren L, et al. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands. Drug Saf. 2022. PMID: 35314943. doi:10.1007/s40264-022-01151-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。